New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC[*] patients Comprehensive immunogenicity data demonstrate TG4050’s ...

Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal 'Vaccines ...

Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response ... next-generation immune checkpoint modulators and effector function-enhanced ...

NUTLEY, N.J., Nov. 3, 2025 /PRNewswire/ -- Eisai announced today the presentation of clinical research in gynecologic oncology during the International Gynecologic Cancer Society (IGCS) 2025 Annual ...

Once thought to be a flaw in the system, new research suggests that CD4 T cells may actually hold the key to maintaining a ...

T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of all adult cancers, remain a ...

Researchers at Moffitt Cancer Center have developed a novel biomaterial-based system that induces the formation of tertiary ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, ...

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

Cancer patients face heightened infection risks due to immunosuppression, necessitating preventive strategies like vaccination despite reduced efficacy. Timing of vaccination is criticall, with ...